Valuation: Contineum Therapeutics, Inc.

Market Cap 380M 345M 319M 288M 543M 35.65B 562M 3.83B 1.52B 19.13B 1.42B 1.39B 60.6B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 152M 138M 128M 115M 218M 14.29B 225M 1.54B 609M 7.67B 571M 559M 24.29B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.98%
Yield 2026 *
-
Yield 2027 * -
1 day-1.93%
1 week-6.12%
Current month+2.98%
1 month+36.58%
3 months-31.85%
6 months-29.52%
Current year-15.40%
1 week 9.36
Extreme 9.36
10.9
1 month 6.72
Extreme 6.725
10.9
Current year 6.72
Extreme 6.725
17.78
1 year 6.72
Extreme 6.725
17.78
3 years 3.35
Extreme 3.35
22
5 years 3.35
Extreme 3.35
22
10 years 3.35
Extreme 3.35
22
Manager TitleAgeSince
Chief Executive Officer 50 2018-09-30
Chief Tech/Sci/R&D Officer 57 2018-02-28
Director of Finance/CFO 51 2020-08-31
Director TitleAgeSince
Chairman 50 2018-09-30
Director/Board Member 47 2019-10-31
Director/Board Member 49 2020-07-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Exercice

Chief Executive Officer

7,500 0.0228%
8/3/26 Exercice

Chief Executive Officer

7,500 0.0229%
7/9/26 Exercice

Founder

75 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%-6.12%-9.29% - 380M
-1.29%-3.91%+51.98%+69.06% 65.56B
-0.09%+2.79%+12.54%+95.02% 60.41B
+0.63%+1.64%+23.11%+89.70% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
+2.35%-3.61%+80.65%+60.70% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.32%-2.08%+31.62%+177.27% 41B
Weighted average by Cap. -0.27%-1.58%+35.53%+151.48%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt -228M -207M -191M -172M -326M -21.36B -337M -2.3B -910M -11.46B -854M -836M -36.31B -274M -249M -230M -207M -391M -25.69B -405M -2.76B -1.09B -13.79B -1.03B -1B -43.67B
Projected Income Statement - Annual - Contineum Therapeutics, Inc.
Logo Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Employees
51
Date Price Change Volume
26-11-16 US$9.670 -1.93% 348,146
26-11-13 US$9.860 +0.82% 265,893
26-11-12 US$9.780 -9.19% 315,430
26-11-11 US$10.77 +1.99% 287,648
26-11-10 US$10.56 +2.52% 249,721
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.670USD
Average target price
21.43USD
Spread / Average Target
+121.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Contineum Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CTNM Stock